Doseology Sciences(DE:VU70)
€0.03+0.00 (+37.50%)
DE:VU70
Doseology Sciences financials statements
€0.03
At close:+0.00 (+37.50%)
Doseology Sciences (VU70) Ratios
0 Followers
Doseology Sciences Ratios
DE:VU70's free cash flow for Q4 2025 was C$-101.79K. For the 2025 fiscal year, DE:VU70's free cash flow was increased by C$0.00 and operating cash flow was C$-101.79K. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.85 | 13.36 | 14.66 | 13.58 | 1.82 |
| Quick Ratio | 15.67 | 13.36 | 14.57 | 13.53 | 1.77 |
| Cash Ratio | 15.19 | 12.85 | 14.21 | 8.56 | 1.36 |
| Solvency Ratio | -4.76 | -3.87 | -17.29 | -2.07 | -0.45 |
| Operating Cash Flow Ratio | -3.64 | -2.85 | -5.25 | -7.82 | -0.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -11.27 | -18.31 | -83.01 |
| Net Current Asset Value | C$ 1.40M | C$ 1.02M | C$ 1.24M | C$ 2.10M | C$ 1.59M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.04 | 0.19 | 0.11 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.04 | 0.25 | 0.27 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.04 | 0.20 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.08 | 1.08 | 1.29 | 2.32 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -21.31 | -10.19 | -15.13 |
| Interest Coverage Ratio | 0.00 | 0.00 | -23.03 | -23.97 | -22.90 |
| Debt to Market Cap | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 |
| Net Debt to EBITDA | 3.03 | 3.32 | 0.70 | 0.65 | 2.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 44.38% | 73.17% | 95.82% | -924.59% | 0.00% |
| EBIT Margin | -1108.20% | -344.95% | -4275.35% | -11612.33% | 0.00% |
| EBITDA Margin | -1108.20% | -324.27% | -4121.96% | -10742.83% | 0.00% |
| Operating Profit Margin | -1108.20% | -383.30% | -1931.33% | -11320.05% | 0.00% |
| Pretax Profit Margin | -1052.23% | -344.95% | -4134.66% | -12084.50% | 0.00% |
| Net Profit Margin | -1052.23% | -344.95% | -4134.66% | -12084.50% | 0.00% |
| Continuous Operations Profit Margin | -1052.23% | -344.95% | -4134.66% | -12084.50% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 94.95% | 89.99% | 214.08% | 106.75% | 103.98% |
| Return on Assets (ROA) | -30.02% | -30.83% | -127.36% | -50.12% | -27.15% |
| Return on Equity (ROE) | -32.04% | -33.33% | -137.08% | -64.69% | -63.13% |
| Return on Capital Employed (ROCE) | -33.74% | -37.03% | -63.66% | -49.77% | -48.35% |
| Return on Invested Capital (ROIC) | -33.74% | -37.03% | -56.51% | -47.34% | -47.51% |
| Return on Tangible Assets | -30.02% | -30.83% | -127.36% | -50.30% | -27.53% |
| Earnings Yield | -9.25% | -53.15% | -144.49% | -7.26% | -1.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.03 | 42.76 | 2.52 | 0.19 | 0.00 |
| Payables Turnover | 0.54 | 0.56 | 0.09 | 1.81 | 1.53 |
| Inventory Turnover | 1.39 | 0.00 | 0.21 | 15.82 | 0.72 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.77 | 0.02 | 0.00 |
| Asset Turnover | 0.03 | 0.09 | 0.03 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.04 | 0.09 | 0.02 | 0.01 | 0.00 |
| Cash Conversion Cycle | -66.12 | -641.77 | -2352.01 | 1764.28 | 269.64 |
| Days of Sales Outstanding | 353.27 | 8.54 | 144.85 | 1942.63 | 0.00 |
| Days of Inventory Outstanding | 262.71 | 0.00 | 1740.13 | 23.07 | 508.84 |
| Days of Payables Outstanding | 682.09 | 650.30 | 4237.00 | 201.43 | 239.20 |
| Operating Cycle | 615.97 | 8.54 | 1884.99 | 1965.70 | 508.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.07 | -0.06 | -0.12 | -0.04 | -0.06 |
| Free Cash Flow Per Share | -0.07 | -0.06 | -0.12 | -0.04 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -120263.50 | -217.29 | -13.92 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -120263.50 | -217.29 | -13.92 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | -9.57 | -2.29 | -3.44 |
| Operating Cash Flow to Sales Ratio | -8.04 | -2.39 | -11.16 | -106.63 | 0.00 |
| Free Cash Flow Yield | -7.07% | -36.77% | -39.01% | -6.44% | -2.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.80 | -1.88 | -0.69 | -13.77 | -75.62 |
| Price-to-Sales (P/S) Ratio | 113.73 | 6.49 | 28.62 | 1664.56 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.46 | 0.63 | 0.95 | 8.91 | 47.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.14 | -2.72 | -2.56 | -15.54 | -48.46 |
| Price-to-Operating Cash Flow Ratio | -14.14 | -2.72 | -2.56 | -15.61 | -51.94 |
| Price-to-Earnings Growth (PEG) Ratio | -0.49 | 0.02 | -0.00 | -0.73 | -0.27 |
| Enterprise Value Multiple | -7.23 | 1.32 | 0.01 | -14.84 | -81.86 |
| Enterprise Value | 3.41M | -420.80K | -18.20K | 25.58M | 119.95M |
| EV to EBITDA | -7.23 | 1.32 | 0.01 | -14.84 | -81.86 |
| EV to Sales | 80.14 | -4.27 | -0.42 | 1594.25 | 0.00 |
| EV to Free Cash Flow | -9.96 | 1.79 | 0.04 | -14.88 | -47.26 |
| EV to Operating Cash Flow | -9.96 | 1.79 | 0.04 | -14.95 | -50.65 |
| Tangible Book Value Per Share | 0.30 | 0.24 | 0.32 | 0.07 | 0.06 |
| Shareholders’ Equity Per Share | 0.30 | 0.24 | 0.32 | 0.07 | 0.06 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 |
| Net Income Per Share | -0.10 | -0.08 | -0.43 | -0.05 | -0.04 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.95 | 1.00 | 0.97 | 1.04 | 1.04 |
| Research & Development to Revenue | 0.07 | 0.00 | 0.01 | 3.85 | 0.00 |
| SG&A to Revenue | 10.04 | 2.38 | 13.62 | 79.49 | 0.00 |
| Stock-Based Compensation to Revenue | 2.29 | 0.18 | 1.94 | 5.35 | 0.00 |
| Income Quality | 0.76 | 0.69 | 0.27 | 0.88 | 1.46 |
Currency in CAD
